<DOC>
	<DOCNO>NCT01876862</DOCNO>
	<brief_summary>During ERAMUNE-01 -02 study , HIV-DNA quantification PBMCs ( Peripheral Blood Mononuclear Cells ) show showed patient low undetectable reservoir . Recent study show low reservoir associate spontaneous virologic control three specific category patient : - `` Elite Controllers '' : rare patient able spontaneously maintain HIV-RNA viral load 50 copies/mL elevate CD4 count without treatment . These patient belong B27/B57 haplotype associate reduce risk HIV contamination haplotype rare global population ( 0,3 % ) - `` Visconti '' patient : early-treated patient , primo-infection stage . After 3 5 year treatment , patient able maintain undetectable HIV-RNA viral load . - `` Salto '' patient : patient treat bit late compare Visconti cohort , CD4 count 350 cells/mm3 HIV-RNA viral load 50 000 copies/mL . The follow-up patient show capacity control HIV infection least 2 year follow treatment interruption . Taking account 3 category patient common characteristic low reservoir , objective answer 2 follow question : 1 . Is possible discontinue treatment chronically-infected patient `` normal '' immune system undetectable HIV-DNA reservoir ? 2 . Is low viral reservoir predictive treatment-free remission HIV infection chronically-infected patient ? The main objective proof-of-concept ERAMUNE-03 trial evaluate proportion patient success ( i.e . able maintain virologic immunologic control infection ) treatment discontinuation , failure define : - An HIV-RNA viral load &gt; 400 copies/mL 2 consecutive test start Week 4 - Or CD4 count &lt; 400 cells/mm3 2 consecutive measure start Week 4 - Or onset AIDS-related event</brief_summary>
	<brief_title>Towards HIV Functional Cure</brief_title>
	<detailed_description />
	<criteria>HIV1 infect patient CD4 count &gt; 500 cells/mm3 CD4/CD8 ratio &gt; 0.9 CD4 nadir &gt; 300 cells/mm3 HIV1RNA plasma viral load &lt; 50 copies/mL antiretroviral treatment least 2 year HIV1RNA plasma viral load &lt; 20 copies/mL baseline HIVDNA reservoir &lt; 100 copies/million PBMCs Signed fully inform consent form Ability attend complete schedule assessment patient visit Patient eligible national social insurance Medical history AIDSstaging event Antiretroviral treatment initiated primoinfection absence antiHIV antibody ( negative ELISA Western Blot test ) Change antiretroviral treatment combination within 3 month prior inclusion HIV2 coinfection History thrombocytopenia ( &lt; 100 000 cells/mm3 ) Acute neurologic event primoinfection Chronic active hepatitis B define positive HBs antigen positive isolated antiHBc antibody Chronic active hepatitis C define positive antiHCV antibody positive HCVRNA PCR History cancer within 5 year prior inclusion except basocellular cutaneous cancer Comorbidity associate lifespan &lt; 12 month accord investigator 's opinion History autoimmune disease ( lupus erythematous , Hashimoto 's thyroiditis , ... ) Hemoglobin &lt; 7 g/dL , Creatinine clearance &lt; 60 mL/min use MDRD formula Patients refusal use condom sexual relationship course study Refusal woman childbearing potential use least one additional barrier method condom Ongoing pregnancy document positive blood test perform screen later Lactating woman Psychologic unstability patient stateofmind incompatible participation study evaluate psychologist screen Drug alcohol addiction abuse Concomitant participation another trial involve investigational treatment device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>chronic infection</keyword>
	<keyword>cure</keyword>
	<keyword>remission</keyword>
</DOC>